Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Adult
Aged
Antiviral Agents
/ adverse effects
Azithromycin
/ adverse effects
Drug Combinations
Drug Prescriptions
/ statistics & numerical data
Female
France
Hospitals, Teaching
/ statistics & numerical data
Humans
Hydroxychloroquine
/ adverse effects
Lopinavir
/ adverse effects
Male
Middle Aged
Pandemics
Patient Safety
Pharmacists
Physicians
Retrospective Studies
Ritonavir
/ adverse effects
COVID-19 Drug Treatment
drug misuse
drug-related side effects and adverse reactions
evidence-based medicine
hospital
pharmacy service
quality of health care
Journal
European journal of hospital pharmacy : science and practice
ISSN: 2047-9956
Titre abrégé: Eur J Hosp Pharm
Pays: England
ID NLM: 101578294
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
09
07
2020
revised:
23
10
2020
accepted:
02
11
2020
pubmed:
27
11
2020
medline:
10
9
2021
entrez:
26
11
2020
Statut:
ppublish
Résumé
The aims of this study were to describe prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis (primary endpoint), then to characterise pharmaceutical interventions (PIs) targeted to these medications and evaluate the impact of these PIs on prescribers' practices (secondary end-points). This retrospective observational study was carried out at the University Hospital of Strasbourg (France) from March to April 2020. The analysed population excluded patients from intensive care units but included all other adult patients with COVID-19 who received at least one dose of lopinavir/ritonavir combination, hydroxychloroquine or azithromycin, while inpatients. Analyses were performed by using data extracted from electronic medical records. During the study period, 278 patients were included. A rapid decrease in lopinavir/ritonavir prescriptions was observed. This was accompanied by an increase in hydroxychloroquine and azithromycin prescriptions until the end of March, followed by a decrease leading to the disappearance of these two medications in April. The pharmaceutical analysis of the prescriptions resulted in 59 PIs of which 21 were associated with lopinavir/ritonavir, 32 with hydroxychloroquine and 6 with azithromycin. Regarding the medication-related problems, the most frequent ones were incorrect treatment durations (n=32 (54.2%)), drug interactions with potential torsadogenic reactions (n=14 (23.7%)) and incorrect dosing (n=6 (10.2%)). From the 59 PIs, 48 (81.4%) were accepted and physicians adjusted the medication regimens in a timely manner. This study demonstrated the value-even more meaningful in a crisis situation-of a strong synergy between physicians and pharmacists for patient-safety focused practices.
Identifiants
pubmed: 33239282
pii: ejhpharm-2020-002449
doi: 10.1136/ejhpharm-2020-002449
pmc: PMC7689541
doi:
Substances chimiques
Antiviral Agents
0
Drug Combinations
0
lopinavir-ritonavir drug combination
0
Lopinavir
2494G1JF75
Hydroxychloroquine
4QWG6N8QKH
Azithromycin
83905-01-5
Ritonavir
O3J8G9O825
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
242-247Informations de copyright
© European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.